ストックスクリーナーアプリを入手
16.11
2.26%
-0.235
アフターアワーズ：
16.02
-0.095
-0.59%
前日終値:
$16.35
開ける：
$16.57
24時間の取引高:
1.31M
Relative Volume:
0.95
時価総額：
$842.63M
収益：
$59,000
当期純損益:
$-78.26M
株価収益率:
-2.6434
EPS:
-6.0964
ネットキャッシュフロー:
$-51.46M
1週間 パフォーマンス:
-1.78%
1か月 パフォーマンス:
+14.80%
6か月 パフォーマンス:
-13.85%
1年 パフォーマンス:
+326.13%
1日の値動き範囲:
$15.90
$16.57
1週間の範囲:
$15.90
$17.10
52週間の値動き範囲:
$3.4313
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
16.03 | 859.45M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Wolfe Research | Outperform |
| 2026-04-06 | 開始されました | Citizens | Mkt Outperform |
| 2026-02-02 | 開始されました | Guggenheim | Buy |
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-09-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-05 | 開始されました | TD Cowen | Buy |
| 2025-08-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2025-03-25 | 開始されました | Jefferies | Buy |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-28 | 開始されました | Piper Sandler | Overweight |
| 2025-02-21 | 開始されました | Wedbush | Outperform |
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-10-24 | 開始されました | H.C. Wainwright | Neutral |
| 2024-04-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Avalo Therapeutics Inc (AVTX) 最新ニュース
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
Logos Global (AVTX) discloses 1.675M-share position, 3.2% of stock - Stock Titan
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
RA Capital and principals report 9.99% stake in Avalo Therapeutics (AVTX) - Stock Titan
OrbiMed reports 475,165 Avalo Therapeutics shares (AVTX) at 2.1% - Stock Titan
BVF affiliates report ~2.35M AVTX shares (NYSE: AVTX) under group attribution - Stock Titan
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55 - Moomoo
Caligan Partners and David Johnson report 7.2% stake in Avalo (AVTX) - Stock Titan
T. Rowe Price (AVTX) shows 2.16M shares, 9.5% of Avalo Therapeutics - Stock Titan
Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results - Sahm
Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Avalo Therapeutics stock jumps 33% in pre-market session: Here's why - MSN
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
AVTX Maintains by Citizens -- Price Target Lowered to $55.00 - GuruFocus
AVTX Maintained by Mizuho -- Price Target Raised to $45.00 - GuruFocus
Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
AVTX Maintained by Wedbush -- Price Target Lowered to $34.00 - GuruFocus
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating - Moomoo
Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00 - MarketBeat
Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating - Moomoo
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 - Moomoo
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data - Investing.com UK
Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $35.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data By Investing.com - Investing.com South Africa
Citizens cuts Avalo Therapeutics stock price target on equity financing - Investing.com UK
Citizens cuts Avalo Therapeutics stock price target on equity financing By Investing.com - Investing.com Australia
AVTX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.27, Implies 137% Upside - TradingView
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside - TradingView
Avalon (AVTX) Reports Promising Trial Results for Abdakibart in HS Treatment - GuruFocus
Avalo Therapeutics Q1 Net Loss Narrows - Moomoo
Avalo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and SEC Filings Overview - Minichart
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $48.7, Implies 144% Upside - TradingView
Avalo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa and Raises $431M to Fund Phase 3 Trial - Minichart
Is Avalo Therapeutics (AVTX) Overvalued After Q1 2026 EPS Beat? - GuruFocus
AVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss - marketscreener.com
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary - TradingView
Avalo Therapeutics Inc (AVTX) 財務データ
収益
当期純利益
現金流量
EPS
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):